• News

  PHARMO’s annual report

  PHARMO’s annual report Each year we develop our annual report to inform the healthcare providers that contribute to the PHARMO Database Network about the research and developments at the PHARMO Institute. The full report is available (in Dutch) he...

  PHARMO Magazine

  Please find below our newest PHARMO Magazine. In this online magazine you can read more, amongst other things, about the PHARMO Database Network, our collaboration with the University of Dundee, the renewal of our ISO9001 certification, the COVID-19...

  PHARMO Magazine

  We are proud to offer you the first edition of our new and improved PHARMO Magazine. In this online magazine you can read about our research, our collaborations with universities and other research institutions and upcoming events. Through our st...

• Events

  Annual Conference International Society for Pharmacoepidemiology

  Annual Conference International Society for Pharmacoepidemiology ICPE All AccessVirtual Event ( September 16-17, 2020) We are pleased to announce that PHARMO will present their study ‘Infliximab Use in the Netherlands: Uptake And Characteristic...

• Vacancy

  (Senior) Research Account Manager

  Wil je bijdragen aan meer transparantie in de gezondheidszorg? Heb je ervaring als onderzoeker en heb je affiniteit met het vertalen van de vragen en onderzoek behoeften van de klant naar een onderzoeksvoorstel/-project?Heb je internationale commerc...

• 

  What we do

  As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  Read more
• 

  What we have

  PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

  Read more

Publications

• Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

  Read more

• No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

  Read more

• Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

  Read more

• The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

  Read more